Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events

Hector I Michelena, Luis A. Osorio, Elena Citkowitz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Elevated levels of low-density lipoprotein cholesterol (LDL-C) impair vascular function by a variety of mechanisms. HMG CoA reductase inhibitors (statins) improve endothelial function by lowering LDL-C and possibly by other "pleiotropic" effects. How rapidly statins can lower LDL-C has not been thoroughly studied. Methods: We examined the lipid response to 3 days of high-dose simvastatin in a randomized prospective double-blind placebo-controlled crossover study. Twenty-seven subjects at moderate to high risk for coronary heart disease (CHD) received either simvastatin 80 mg/day for 3 days followed by placebo for 3 days or placebo followed by simvastatin. After a washout period of 10 to 14 days, subjects received the opposite treatment. Nonfasting blood lipid levels, including total cholesterol, direct LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides, were obtained before randomization and after each 3-day treatment period. Results: The mean LDL-C level at baseline was 107 mg/dl and decreased 24% in patients receiving simvastatin and 5.6% in patients receiving placebo (P<0.001). Statistically significant reductions were also achieved in the total cholesterol and cholesterol/HDL-C ratio: 14% and 12%, respectively. Changes in HDL-C and triglyceride levels were not significant. Conclusion: Treatment with simvastatin for only 3 days results in a 24% drop in the LDL-C level. As defined by ATPIII, this decrease is comparable to that necessary to lower the LDL-C from one risk level to a lower one and is, therefore, both clinically and statistically significant.

Original languageEnglish (US)
Pages (from-to)111-114
Number of pages4
JournalInternational Journal of Cardiology
Volume101
Issue number1
DOIs
StatePublished - May 11 2005
Externally publishedYes

Fingerprint

Simvastatin
LDL Cholesterol
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Placebos
HDL Cholesterol
Lipids
Random Allocation
Cross-Over Studies
Coronary Disease
Blood Vessels
Therapeutics

Keywords

  • Coronary heart disease
  • HDL-C
  • HMG CoA
  • LDL-C
  • Reduction
  • Simvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. / Michelena, Hector I; Osorio, Luis A.; Citkowitz, Elena.

In: International Journal of Cardiology, Vol. 101, No. 1, 11.05.2005, p. 111-114.

Research output: Contribution to journalArticle

@article{84501017cc43405ca122e2169dfdf9d9,
title = "Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events",
abstract = "Background: Elevated levels of low-density lipoprotein cholesterol (LDL-C) impair vascular function by a variety of mechanisms. HMG CoA reductase inhibitors (statins) improve endothelial function by lowering LDL-C and possibly by other {"}pleiotropic{"} effects. How rapidly statins can lower LDL-C has not been thoroughly studied. Methods: We examined the lipid response to 3 days of high-dose simvastatin in a randomized prospective double-blind placebo-controlled crossover study. Twenty-seven subjects at moderate to high risk for coronary heart disease (CHD) received either simvastatin 80 mg/day for 3 days followed by placebo for 3 days or placebo followed by simvastatin. After a washout period of 10 to 14 days, subjects received the opposite treatment. Nonfasting blood lipid levels, including total cholesterol, direct LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides, were obtained before randomization and after each 3-day treatment period. Results: The mean LDL-C level at baseline was 107 mg/dl and decreased 24{\%} in patients receiving simvastatin and 5.6{\%} in patients receiving placebo (P<0.001). Statistically significant reductions were also achieved in the total cholesterol and cholesterol/HDL-C ratio: 14{\%} and 12{\%}, respectively. Changes in HDL-C and triglyceride levels were not significant. Conclusion: Treatment with simvastatin for only 3 days results in a 24{\%} drop in the LDL-C level. As defined by ATPIII, this decrease is comparable to that necessary to lower the LDL-C from one risk level to a lower one and is, therefore, both clinically and statistically significant.",
keywords = "Coronary heart disease, HDL-C, HMG CoA, LDL-C, Reduction, Simvastatin",
author = "Michelena, {Hector I} and Osorio, {Luis A.} and Elena Citkowitz",
year = "2005",
month = "5",
day = "11",
doi = "10.1016/j.ijcard.2004.08.021",
language = "English (US)",
volume = "101",
pages = "111--114",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events

AU - Michelena, Hector I

AU - Osorio, Luis A.

AU - Citkowitz, Elena

PY - 2005/5/11

Y1 - 2005/5/11

N2 - Background: Elevated levels of low-density lipoprotein cholesterol (LDL-C) impair vascular function by a variety of mechanisms. HMG CoA reductase inhibitors (statins) improve endothelial function by lowering LDL-C and possibly by other "pleiotropic" effects. How rapidly statins can lower LDL-C has not been thoroughly studied. Methods: We examined the lipid response to 3 days of high-dose simvastatin in a randomized prospective double-blind placebo-controlled crossover study. Twenty-seven subjects at moderate to high risk for coronary heart disease (CHD) received either simvastatin 80 mg/day for 3 days followed by placebo for 3 days or placebo followed by simvastatin. After a washout period of 10 to 14 days, subjects received the opposite treatment. Nonfasting blood lipid levels, including total cholesterol, direct LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides, were obtained before randomization and after each 3-day treatment period. Results: The mean LDL-C level at baseline was 107 mg/dl and decreased 24% in patients receiving simvastatin and 5.6% in patients receiving placebo (P<0.001). Statistically significant reductions were also achieved in the total cholesterol and cholesterol/HDL-C ratio: 14% and 12%, respectively. Changes in HDL-C and triglyceride levels were not significant. Conclusion: Treatment with simvastatin for only 3 days results in a 24% drop in the LDL-C level. As defined by ATPIII, this decrease is comparable to that necessary to lower the LDL-C from one risk level to a lower one and is, therefore, both clinically and statistically significant.

AB - Background: Elevated levels of low-density lipoprotein cholesterol (LDL-C) impair vascular function by a variety of mechanisms. HMG CoA reductase inhibitors (statins) improve endothelial function by lowering LDL-C and possibly by other "pleiotropic" effects. How rapidly statins can lower LDL-C has not been thoroughly studied. Methods: We examined the lipid response to 3 days of high-dose simvastatin in a randomized prospective double-blind placebo-controlled crossover study. Twenty-seven subjects at moderate to high risk for coronary heart disease (CHD) received either simvastatin 80 mg/day for 3 days followed by placebo for 3 days or placebo followed by simvastatin. After a washout period of 10 to 14 days, subjects received the opposite treatment. Nonfasting blood lipid levels, including total cholesterol, direct LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides, were obtained before randomization and after each 3-day treatment period. Results: The mean LDL-C level at baseline was 107 mg/dl and decreased 24% in patients receiving simvastatin and 5.6% in patients receiving placebo (P<0.001). Statistically significant reductions were also achieved in the total cholesterol and cholesterol/HDL-C ratio: 14% and 12%, respectively. Changes in HDL-C and triglyceride levels were not significant. Conclusion: Treatment with simvastatin for only 3 days results in a 24% drop in the LDL-C level. As defined by ATPIII, this decrease is comparable to that necessary to lower the LDL-C from one risk level to a lower one and is, therefore, both clinically and statistically significant.

KW - Coronary heart disease

KW - HDL-C

KW - HMG CoA

KW - LDL-C

KW - Reduction

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=18144392987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144392987&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2004.08.021

DO - 10.1016/j.ijcard.2004.08.021

M3 - Article

C2 - 15860392

AN - SCOPUS:18144392987

VL - 101

SP - 111

EP - 114

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -